Vanda Pharmaceuticals Inc.
VNDA
$3.92
-$0.06-1.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.04M | 53.19M | 47.65M | 50.47M | 47.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.04M | 53.19M | 47.65M | 50.47M | 47.46M |
| Cost of Revenue | 3.52M | 2.59M | 2.55M | 2.73M | 3.44M |
| Gross Profit | 46.52M | 50.60M | 45.10M | 47.74M | 44.02M |
| SG&A Expenses | 50.08M | 39.28M | 37.57M | 39.47M | 30.09M |
| Depreciation & Amortization | 1.75M | 1.75M | 1.75M | 1.75M | 2.02M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.07M | 63.46M | 58.65M | 60.62M | 56.70M |
| Operating Income | -41.03M | -10.28M | -11.00M | -10.15M | -9.24M |
| Income Before Tax | -37.37M | -6.50M | -6.24M | -5.52M | -4.66M |
| Income Tax Expenses | -7.87M | -1.59M | -920.00K | -998.00K | -518.00K |
| Earnings from Continuing Operations | -29.49M | -4.91M | -5.32M | -4.52M | -4.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.49M | -4.91M | -5.32M | -4.52M | -4.15M |
| EBIT | -41.03M | -10.28M | -11.00M | -10.15M | -9.24M |
| EBITDA | -39.05M | -8.31M | -9.03M | -8.18M | -7.01M |
| EPS Basic | -0.50 | -0.08 | -0.09 | -0.08 | -0.07 |
| Normalized Basic EPS | -0.40 | -0.14 | -0.07 | -0.06 | -0.05 |
| EPS Diluted | -0.50 | -0.09 | -0.09 | -0.08 | -0.07 |
| Normalized Diluted EPS | -0.40 | -0.14 | -0.07 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 58.53M | 58.31M | 58.26M | 58.22M | 57.76M |
| Average Diluted Shares Outstanding | 58.53M | 58.31M | 58.26M | 58.22M | 57.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |